Your browser is no longer supported. Please, upgrade your browser.
AVRO AVROBIO, Inc. daily Stock Chart
AVRO [NASD]
AVROBIO, Inc.
Index- P/E- EPS (ttm)-2.62 Insider Own3.52% Shs Outstand31.03M Perf Week21.69%
Market Cap678.94M Forward P/E- EPS next Y-2.73 Insider Trans0.00% Shs Float30.72M Perf Month63.90%
Income-66.30M PEG- EPS next Q-0.61 Inst Own96.40% Short Float3.62% Perf Quarter18.02%
Sales- P/S- EPS this Y-143.20% Inst Trans42.76% Short Ratio5.46 Perf Half Y62.07%
Book/sh6.82 P/B3.21 EPS next Y-7.90% ROA-46.50% Target Price36.56 Perf Year-12.23%
Cash/sh6.65 P/C3.29 EPS next 5Y- ROE-50.20% 52W Range11.85 - 28.52 Perf YTD31.41%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-23.28% Beta-
Dividend %- Quick Ratio21.60 Sales past 5Y- Gross Margin- 52W Low84.72% ATR1.33
Employees73 Current Ratio21.60 Sales Q/Q- Oper. Margin- RSI (14)85.37 Volatility9.52% 7.97%
OptionableYes Debt/Eq0.00 EPS Q/Q-16.00% Profit Margin- Rel Volume1.10 Prev Close21.44
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume203.99K Price21.88
Recom1.80 SMA2032.99% SMA5044.61% SMA20025.89% Volume225,143 Change2.05%
Jun-27-19Initiated Mizuho Buy $28
Apr-05-19Initiated Janney Buy
Oct-10-18Initiated Guggenheim Buy
Oct-02-18Reiterated H.C. Wainwright Buy $47 → $40
Sep-17-18Initiated H.C. Wainwright Buy $47
Jul-16-18Initiated Wells Fargo Outperform $40
Jul-16-18Initiated Wedbush Outperform $38
Jul-16-18Initiated Morgan Stanley Overweight $37
Dec-14-19 07:47PM  Is AVROBIO, Inc. (AVRO) Going to Burn These Hedge Funds? Insider Monkey
Nov-07-19 07:00AM  AVROBIO, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update Business Wire
Nov-06-19 02:31PM  AVROBIO, Inc. (AVRO): Are Hedge Funds Right About This Stock? Insider Monkey
Oct-24-19 07:00AM  AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVRRD02 for the Treatment of Gaucher Disease Business Wire
Oct-22-19 07:00AM  AVROBIO Appoints Holly May as Chief Commercial Officer Business Wire
Oct-16-19 06:02AM  Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation Simply Wall St.
Oct-08-19 07:00AM  AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis Business Wire
Oct-03-19 08:00AM  AVROBIO, Inc. to Present at Chardans 3rd Annual Genetic Medicines Conference Business Wire
Sep-27-19 09:00AM  AVROBIO, Inc. (AVRO) Upgraded to Buy: Here's What You Should Know Zacks -5.53%
Sep-11-19 10:22AM  Moving Average Crossover Alert: AVROBIO Zacks
Aug-29-19 07:00AM  AVROBIO, Inc. to Present at Upcoming Investor Conferences Business Wire
Aug-16-19 08:30AM  AVROBIO Appoints Georgette Verdin as Chief Human Resources Officer Business Wire
Aug-12-19 05:36PM  AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-08-19 07:00AM  AVROBIO Reports Second Quarter 2019 Financial Results and Provides Business Update Business Wire +11.83%
04:02AM  3 Strong Buy Healthcare Stocks Insiders Are Buying Now TipRanks
Aug-06-19 08:00AM  AVROBIO, Inc. to Present at the 2019 Wedbush PacGrow Healthcare Conference Business Wire
Jul-29-19 08:08AM  3 Biotech Stocks Corporate Insiders are Buying TipRanks
Jul-26-19 07:51AM  Will AVROBIO Continue to Surge Higher? Zacks
Jul-19-19 04:01PM  AVROBIO Announces Closing of Underwritten Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire -6.19%
Jul-18-19 05:57AM  Did Changing Sentiment Drive AVROBIO's (NASDAQ:AVRO) Share Price Down By 34%? Simply Wall St.
Jul-17-19 04:26PM  Why Seattle Genetics, AVROBIO, and First Majestic Silver Jumped Today Motley Fool +19.52%
12:35PM  Here's Why Avrobio Rose as Much as 19.9% Today Motley Fool
Jul-16-19 09:58PM  AVROBIO Announces Pricing of Underwritten Public Offering of $120.25 Million of Common Stock Business Wire +16.69%
04:01PM  AVROBIO Announces Proposed Public Offering of Common Stock Business Wire
Jul-15-19 04:28PM  Why Crocs, Golden Star Resources, and AVROBIO Jumped Today Motley Fool +14.99%
07:00AM  AVROBIO Announces 87% Substrate Reduction in First Kidney Biopsy and Additional Positive Data from Clinical Trials of AVR-RD-01 Investigational Gene Therapy in Fabry Disease Business Wire
May-13-19 07:00AM  AVROBIO, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update Business Wire
May-12-19 06:43PM  Heres What Hedge Funds Think About AVROBIO, Inc. (AVRO) Insider Monkey
Apr-29-19 07:00AM  AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry Disease Business Wire
Apr-26-19 04:00PM  AVROBIO Highlights the plato Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy Business Wire
Mar-25-19 07:00AM  AVROBIO, Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update Business Wire
Mar-05-19 07:00AM  AVROBIO, Inc. to Present at the Cowen and Company 39th Annual Health Care Conference Business Wire -6.07%
Feb-06-19 09:00AM  AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease Business Wire
Feb-05-19 02:48PM  Investors Are Undervaluing AVROBIO, Inc. (NASDAQ:AVRO) By 46.82% Simply Wall St. +10.60%
Feb-01-19 07:00AM  AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019 GlobeNewswire +7.70%
Jan-18-19 07:43AM  AVROBIO Enters Oversold Territory Zacks +5.86%
07:00AM  AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis GlobeNewswire
Jan-17-19 07:00AM  AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019 GlobeNewswire -7.88%
Jan-07-19 07:06AM  AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors GlobeNewswire -5.62%
Dec-21-18 10:00AM  AVROBIO, Inc. Added to NASDAQ Biotechnology Index GlobeNewswire -12.12%
12:41AM  Should You Avoid AVROBIO, Inc. (AVRO)? Insider Monkey
Dec-19-18 07:00AM  AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR RD 01 for the Treatment of Fabry Disease GlobeNewswire -7.88%
Dec-18-18 07:05AM  AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
07:00AM  AVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management Hires GlobeNewswire
Nov-28-18 01:05PM  Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns' Benzinga
Nov-21-18 07:35AM  Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +9.16%
Nov-13-18 08:00AM  AVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire +5.79%
Oct-04-18 04:01PM  AVROBIO, Inc. to Present at Chardan's 2nd Annual Genetic Medicines Conference GlobeNewswire
Oct-01-18 07:01AM  AVROBIO Receives No Objection to Clinical Trial Application from Health Canada for AVR-RD-02 Gene Therapy for Gaucher Disease GlobeNewswire -51.55%
07:00AM  AVROBIO Announces Updated Clinical Data for AVR-RD-01 Gene Therapy in Fabry Disease GlobeNewswire
Aug-09-18 08:00AM  AVROBIO, Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Aug-08-18 08:00AM  AVROBIO, Inc. to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-16-18 10:52AM  Newly Public Gene Therapy Biotech Avrobio Picks Up 2 Sell-Side Bulls Benzinga
Jun-27-18 08:00AM  AVROBIO, Inc. Appoints Phillip B. Donenberg to its Board of Directors GlobeNewswire
Jun-25-18 04:30PM  AVROBIO, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Overallotment Option GlobeNewswire
Jun-22-18 08:13PM  [$$] Five Drug Startups Reveal Plans to Join Blitz of Biotech IPOs The Wall Street Journal
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 10:01PM  [$$] Eidos Therapeutics Goes Public, Joining Biotech IPO Flurry The Wall Street Journal
08:42PM  AVROBIO, Inc. Announces Pricing of Initial Public Offering GlobeNewswire
03:11PM  8 Biotech Stocks With IPOs This Week InvestorPlace
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.